Skip to main content
. Author manuscript; available in PMC: 2012 Aug 15.
Published in final edited form as: Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 13;35(7):1753–1764. doi: 10.1016/j.pnpbp.2011.06.004

Figure 4.

Figure 4

Effect of haloperidol treatment on antisaccade performance in impaired and nonimpaired schizophrenia subgroups versus an unmedicated control group. (A, B) Average latency in the antisaccade task for impaired and nonimpaired schizophrenic subgroups and control group when the schizophrenia subgroups are defined by the median split (A) and the standard deviation based split (B). (C, D) Average error rate in the antisaccade task for impaired and nonimpaired schizophrenic subgroups and control group when the schizophrenia subgroups are defined by the median split (C) and the standard deviation based split (D). Data shown are from baseline (white bar), short (gray bar) and long (black bar) sessions. Error bars represent 1 SEM.